Knight Therapeutics (TSE:GUD) Sets New 12-Month High – What’s Next?

Knight Therapeutics Inc. (TSE:GUD) shares hit a new 52-week high on Thursday. The stock traded as high as C$11.84 and last traded at C$11.59, with a volume of 3,125 shares. The stock had previously closed at C$11.26.

Knight Therapeutics Trading Down 1.2%

The company has a fifty day moving average of C$10.60 and a two-hundred day moving average of C$8.67. The stock has a market capitalization of C$1.12 billion, a price-to-earnings ratio of 76.13, a P/E/G ratio of -1,013.50 and a beta of -0.51. The company has a quick ratio of 1.79, a current ratio of 2.28 and a debt-to-equity ratio of 4.29.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, November 5th. The company reported C($0.03) earnings per share for the quarter. The firm had revenue of C$136.74 million during the quarter. Knight Therapeutics had a net margin of 2.72% and a return on equity of 1.91%. On average, research analysts expect that Knight Therapeutics Inc. will post 0.10 EPS for the current year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.